Table 3.
Incidence rate ratio and combined estimate for β-adrenoreceptor modulators and parkinsonism in each database
| Medication | Database | IRR (95% CI) |
|---|---|---|
| Albuterol | Optum® | 0.83 (0.72–0.97) |
| CCAE | 0.76 (0.53–1.07) | |
| MDCR | 0.89 (0.75–1.05) | |
| MDCD | 0.69 (0.5–0.96) | |
| Combined | I2 = 0 | 0.83 (0.75–0.92) |
| Carvedilol | Optum® | 0.92 (0.81–1.03) |
| CCAE | 1.03 (0.73–1.47) | |
| MDCR | 0.89 (0.79–1.0) | |
| MDCD | 0.57 (0.41–0.79) | |
| Combined | I2 = 60.7% | 0.86 (0.74–1.0) |
| Metoprolol | Optum® | 0.97 (0.9–1.04) |
| CCAE | 1.03 (0.87–1.22) | |
| MDCR | 0.92 (0.86–1.0) | |
| MDCD | 0.78 (0.62–0.98) | |
| Combined | I2 = 22.7 | 0.94 (0.89–0.99) |
| Propranolol | Optum® | 1.32 (1.18–1.49) |
| CCAE | 1.72 (1.44–2.05) | |
| MDCR | 1.37 (1.19–1.59) | |
| Truven MDCD | 0.83 (0.6–1.14) | |
| Combined | I2 = 81.4% | 1.32 (1.09–1.60) |
CCAE IBM MarketScan® Commercial Claims and Encounters Database, CI confidence interval, IRR incidence rate ratio, MDCD IBM MarketScan® Multi-State Medicaid Database, MDCR IBM MarketScan® Medicare Supplemental Database, Optum® Optum® De-Identified Clinformatics® Data Mart Database